On July 18, 2026 MediLink Therapeutics (Suzhou) Co., Ltd. reported that the New Drug Application (NDA) for its independently developed B7-H3-targeting antibody-drug conjugate (ADC) Tam-Peli (research code: YL201) has been accepted for review by the National Medical Products Administration (NMPA). The submission is for the treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have previously failed PD-(L)1 inhibitors and at least two lines of chemotherapy. The application is based on the prespecified interim analysis results from a randomized, controlled, multicenter Phase III study, YL201-CN-301-01 (TAISHAN-301), comparing YL201 versus investigator’s choice of chemotherapy in this patient population.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Xue Tongtong, CEO of MediLink , commented: "The formal acceptance of YL201’s NDA by the CDE marks a significant milestone for MediLink as we transition from clinical development toward commercialization. It is also an important testament to our team’s innovation and execution capabilities. We fully recognize that patients in the later-line NPC setting have extremely limited treatment options and face a huge unmet medical need. We are fully committed to cooperating with the regulatory review process and striving to bring this internationally competitive innovative therapy to Chinese patients as soon as possible."
Current Status of Advanced Nasopharyngeal Carcinoma Treatment
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from the epithelial lining of the nasopharynx, primarily associated with Epstein–Barr virus (EBV) infection, genetic predisposition, and environmental factors. NPC exhibits significant racial and geographic disparities. Among the three major racial groups worldwide, Asian populations have the highest incidence, followed by Black populations, while NPC is extremely rare in Caucasians. According to World Health Organization (WHO) data published in 2022, China bears a heavy disease burden of NPC: approximately half of global new cases (51,000 out of 120,000) and over one-third of global deaths (28,000 out of 73,000) occur in China, placing the country’s morbidity and mortality burden among the highest worldwide [1][2].
About Tam-Peli
Tam-Peli (YL201) is an ADC targeting B7-H3, developed using MediLink ‘s proprietary TMALIN (Tumor Microenvironment-Activable Linker-payload) platform, which features a tumor-cleavable camptothecin-based linker-payload technology. In January 2026, Yilong Biomedical entered into an exclusive licensing agreement with Roche for the YL201 program, granting Roche exclusive global development, manufacturing, and commercialization rights outside mainland China, Hong Kong SAR, and Macau SAR. The two parties will jointly accelerate global R&D and regulatory filings, advancing development and commercialization across multiple solid tumor indications. Under the agreement, MediLink received an upfront payment and near-term milestones totaling $570 million, and is eligible for additional development, regulatory, and commercial milestone payments, as well as tiered royalties on net overseas sales.
On May 23, 2026, MediLink announced that in the Phase III trial for recurrent/metastatic NPC (TAISHAN-301), an Independent Data Monitoring Committee (IDMC) confirmed that the prespecified interim analysis had met the co-primary endpoint of objective response rate (ORR) assessed by blinded independent central review (BICR). This is the first positive Phase III result globally for a B7-H3 ADC.
Currently, YL201 is being evaluated in global clinical studies across multiple advanced solid tumor types. In China, YL201 has initiated three separate Phase III registrational trials for NPC, small cell lung cancer (SCLC), and esophageal squamous cell carcinoma (ESCC). Previously, YL201 has received five Breakthrough Therapy Designations from the NMPA’s Center for Drug Evaluation (CDE) for indications including SCLC, NPC, ESCC, and pancreatic cancer, as well as a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SCLC. In addition, YL201 has been granted three Orphan Drug Designations by the FDA for SCLC, NPC, and ESCC.
(Press release, Suzhou Medilink Therapeutics, JUL 18, 2026, View Source [SID1234669368])